Eli Lilly

Eli Lilly shares dropped sharply Friday, falling more than 14% in early trading after clinical trial data for its oral obesity drug orforglipron missed market expectations. Despite the decline, Wall Street analysts remain broadly positive ... more

Eli Lilly's shares soared as the company reported second-quarter earnings that far exceeded expectations, driven by high demand for its diabetes drug Mounjaro and weight loss injection Zepbound. Eli Lilly reported impressive second-quarter earnings on ... more